LAB.00037 Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS)

This policy addresses serologic testing for irritable bowel syndrome (IBS) biomarkers such as anti-CdtB and anti-vinculin, including ibs-smart and IBSchek. Anthem deems these tests investigational/experimental and not medically necessary; they are not covered for any use, including screening, diagnosis, or management of IBS. There are no covered indications or exceptions, regardless of test setting (venipuncture or home-based collection).

"Serological testing for biomarkers of irritable bowel syndrome (for example, CdtB and anti-vinculin), is consideredinvestigational and not medically necessaryfor screening, diagnosis or management ..."

Sign up to see full coverage criteria, indications, and limitations.